Research Articles >
College of Health Sciences >
Please use this identifier to cite or link to this item:
|Title: ||Buruli Ulcer: a Review of the Current Knowledge|
|Authors: ||Phillips, Richard O.|
Yotsu, Rie R.
Simmonds, Rachel E.
|Keywords: ||Buruli ulcer|
Non-tuberculous mycobacterial disease
Skin neglected tropical diseases
|Issue Date: ||28-Sep-2018|
|Publisher: ||Current Tropical Medicine Reports|
|Citation: ||Current Tropical Medicine Reports (2018) 5:247–256 https://doi.org/10.1007/s40475-018-0166-2|
|Abstract: ||Purpose of the Review Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans,
one of the skin-related neglected tropical diseases (skin NTDs). This article aims to review the current knowledge of this disease
and challenges ahead.
Recent Findings Around 60,000 cases of BU have been reported from over 33 countries between 2002 and 2017. Encouraging
findings for development of point-of-care tests for BU are being made, and its treatment is currently in the transition period from
rifampicin plus streptomycin (injection) to all-oral regimen. A major recent advance in our understanding of its pathogenesis has
been agreement on the mechanismof action of the major virulence toxin mycolactone in host cells, targeting the Sec61 translocon
during a major step in protein biogenesis.
Summary BU is distributed mainly in West Africa, but cases are also found in other parts of the world. We may be
underestimating its true disease burden, due to the limited awareness of this disease. More awareness and more understanding
of BU will surely contribute in enhancing our fight against this skin NTD.|
|Description: ||An article published by Current Tropical Medicine Reports and available at doi.org/10.1007/s40475-018-0166-2|
|Appears in Collections:||College of Health Sciences|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.